Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Remedy's Control Resonant to be launched in three weeks – what to keep an eye on in its lead-up?

REMEDYAnalyst Comment03.09.2026 klo 10.12
Atte RiikolaAnalyst
Discuss

Summary

  • Remedy's upcoming release, Control Resonant, on September 24, is pivotal for the company's investment case, potentially enabling self-publishing of future projects and enhancing the Control brand's value.
  • Metacritic reviews, expected shortly before the release, are crucial indicators of the game's quality; a score above 85 could signal a hit, while scores below 80 may risk not meeting sales forecasts.
  • Initial PC data from Steam, including concurrent players and user reviews, will provide early insights into the game's reception, though console sales, particularly on PS5, remain significant but less visible.
  • The release window is crowded, with competitors like Marvel's Wolverine and Silent Hill: Townfall launching around the same time, potentially impacting Control Resonant's market performance.

This content is generated by AI. You can give feedback on it in the Inderes forum.

Translation: Original published in Finnish on 9/3/2026 at 8:19 am EEST.

Remedy will release Control Resonant on September 24. The game represents a turning point for the company's investment case, as a successful launch would also enable the self-publishing of subsequent projects and further strengthen the value and long-term potential of the Control game brand, in our view. Based on the data points provided by Remedy in its Q2 report, we believe the game is on its way to commercial success, and the hit game option is still present. Although Remedy’s stock has been rising recently, we still see clear potential if Control Resonant becomes a commercial success. In fact, this success would increase the likelihood of future game successes for Remedy as well, and the stock could see a clear level correction if the stock market began to price in this longer-term potential more strongly. Next, we’ll review a few things investors should keep an eye on before and after Control Resonant's release.

Metacritic reviews will likely be available right before release

The Metacritic reviews from critics, typically released a few days before a game's launch, are an important indicator of a game's quality, though they alone do not guarantee success. Alan Wake 2 was a critical success (Metacritic 89) but its commercial success (over 3 million copies sold to date) has fallen short of the critics' ratings. This is partly due to the game's absence from the Steam platform because Epic Games is the publisher.

Based on our rough estimate, a Metacritic score above 85 would mean that there is potential for Control Resonant to become a hit, and the game’s sales trajectory over the next several years would likely be strong. With an average review score of 80–84, we believe the game could meet our current sales forecasts (2026e: 1.9 million copies; 2027e: 2.2 million copies). In our view, ratings below this level would increase the risk of not realizing our current forecasts.

PC data from the first weekend provides some insight into how the game was received

Data available from Steam immediately after the release of the game is one of the best ways to monitor its reception. The number of concurrent players and user reviews provide some indication of the game's success after the first weekend. However, console platforms (particularly the PS5) are also extremely important for sales, and there is limited external visibility into them.

Before the game's release, it is also helpful to monitor the development of the game's wishlist ranking on Steam. In its Q2 report, Remedy stated that, as of August 11, the game had garnered over 1.5 million wishlist entries across all platforms. Currently, the game is ranked 27th on Steam's wishlist charts, and we believe it will continue to rise towards its release.

In terms of Steam data, China is an interesting wild card for Remedy. In its Q2 report, Remedy stated that the Chinese-language market accounted for the second-highest number of pre-orders on Steam. If the volume were heavily weighted towards China, the number of copies sold could exceed our estimate, but sales in euros might not because regional pricing weighs on the average price.

This fall's release window is packed

September is an exceptionally busy month, as game companies are avoiding GTA 6 (due to be released on Nov. 19), which will capture all the attention at the end of the year. Before Control Resonant, there are three useful peer games to monitor.

The Blood of Dawnwalker (Sept. 3) is a story-driven, single-player game from the new studio Rebel Wolves, whose team includes former creators of The Witcher 3. The game received positive reviews (Metacritic PC/PS5:  83–84), making it a relevant competitor to Resonant.  

Onimusha: Way of the sword (Sept. 4) is interesting for its timing alone. Capcom moved the release date up by three weeks from the original date of September 25, effectively taking it out of Resonant's release window. The game has also received positive reviews (Metacritic PC/PS5: 83–86), so it will also compete with Resonant for players' time and money in September.

One of Resonant's main competitors is Marvel's Wolverine (Sept. 15), which, however, will be released exclusively on the PlayStation platform. Nevertheless, this popular IP, developed by a well-known game studio (Insomniac), will likely capture the attention of a large audience and compete with Resonant for players' money just 9 days before its release.  On the same day as Control Resonant, September 24, Silent Hill: Townfall will also be released, but it differs from Resonant in genre (horror).

Login required

This content is only available for logged in users

Create account

Remedy Entertainment is a game developer. Its operations are primarily focused on the development of action games, with a particular focus on 3D technology. Examples of games that the company has developed include several different versions of Alan Wake, Max Payne, and Control. Remedy also develops its own game engine and tooling technology that powers many of its games. The company was founded in 1995 and is headquartered in Espoo, Finland.

Read more on company page

Key Estimate Figures12.08.

202526e27e
Revenue59.5125.2121.7
growth-%17.5 %110.4 %-2.8 %
EBIT (adj.)-14.95.015.0
EBIT-% (adj.)-25.0 %4.0 %12.3 %
EPS (adj.)-0.960.250.86
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.76.622.0
EV/EBITDA17.29.48.1

Forum discussions

There’s probably a bit of that PS Early Access distortion here too, since they were able to start a few days earlier than others. People have...
1 hour ago
by Aruzo
6
I was thinking that since Metacritic has 280 user reviews for consoles and 44 for PC, would it be safe to draw the conclusion that consoles ...
2 hours ago
by Hasty
18
Rises like a phoenix from the ashes. Well, at least compared to Control 1 if nothing else
3 hours ago
by timontti
21
Inderes’s forecast on August 12, 2026, was 1.1 million copies by next Thursday (when Q3 ends). At that time, the number of wishlists was 1.5...
3 hours ago
by Miika21
2
With all due respect @MyrtsiZzz, but I trust that AI assessment about as much as the positive and constructive atmosphere in the politics thread
4 hours ago
48
Low-effort post, but my gut feeling is that the one-million sales mark will be reached as early as Monday, so I asked someone smarter than myself...
4 hours ago
by MyrtsiZzz
8
Following CCU, it looks like a tight release window is eating into Resonant’s launch a bit. There’s still a lot of Onimusha being played in ...
6 hours ago
by Keijo Hannula
10